Ugli Tablet 15 mg (Pioglitazone Hydrochloride)
Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
YuYu Pharmaceutical Co., Ltd.
MFDS item code 201903308 · Approved 2019.05.22
This product's status changed to Expired on 2024.05.22. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to help control blood sugar levels in patients with type 2 diabetes. It can be administered as monotherapy along with dietary and exercise regimens, and in cases of insufficient improvement in blood sugar, it can be combined with sulfonylureas, metformin, or insulin. Nutritional counseling, weight loss, and regular exercise also play a vital role in diabetes treatment. This comprehensive treatment approach helps effectively regulate blood sugar and maintain the efficacy of drug therapy. Therefore, this medication is used to improve blood sugar control in patients with type 2 diabetes.
This drug is administered orally once daily, with or without food. Management of diabetes should be individualized for each patient. Ideally, response to treatment should be assessed by monitoring glycated hemoglobin (HbA1c), which is a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the previous 2 ~ 3 months. Clinically, this drug should be administered for an appropriate period (at least 3 months) to patients with diabetes to evaluate changes in glycated hemoglobin, provided that their blood glucose control does not worsen. 1. Monotherapy This drug may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose of this drug does not provide sufficient efficacy, the dose may be increased to up to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This drug may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When this drug is used in combination, the current sulfonylurea may be continued at the same dosage regimen. However, if the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This drug may be administered in combination with metformin; the initial dose is 15 mg once daily. When this drug is used in combination, the current metformin may be continued at the same dosage regimen. It is unlikely that the metformin dose will need to be adjusted because of symptoms of hypoglycemia during combination therapy with this drug. 3) Insulin: This drug may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be maintained when combination therapy with this drug is initiated. However, if a patient receiving this drug in combination with insulin develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or less, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to the degree of blood glucose control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see Precautions, Patients with Renal Impairment). If, at the start of treatment, the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (at least 2.5 times the upper limit of normal for ALT), therapy with this drug should not be initiated (see Adverse Reactions and Precautions, Effects on the Liver). Monitoring of liver enzymes is recommended in all patients before initiation of therapy with this drug and periodically thereafter. There are no data on the administration of this drug in combination with other thiazolidinediones.
Use is not recommended in children under 18 years of age because there is no experience with its use in this population.
This medication is used for treating type 2 diabetes and requires insulin to lower blood sugar levels. It may worsen or newly induce heart failure, thus it should not be used in patients with heart failure, and symptoms of heart failure such as sudden weight gain, shortness of breath, and edema should be closely monitored during treatment. Fluid retention may occur, which can lead to swelling, so if there is severe swelling or signs of heart failure, consult a doctor immediately. This medication should not be administered to patients with bladder cancer or a history of bladder cancer, and if symptoms such as hematuria or urinary difficulties develop during treatment, inform a physician immediately. Patients with impaired liver function or severe renal impairment should generally avoid this medication, and if symptoms of liver dysfunction appear, treatment should be stopped, and medical consultation is advised. The risk of hypoglycemia may increase when used with other blood glucose-lowering agents, especially insulin or sulfonylureas, so symptoms of hypoglycemia should be monitored, and doses of other medications may need adjustment. In premenopausal women, this medication may promote ovulation, increasing the risk of pregnancy, so appropriate contraception should be employed. Use with caution in elderly patients or those with reduced kidney function, and regular blood glucose and liver function tests are essential. During treatment, weight gain and edema may occur, so monitor weight changes closely, and consult a doctor if any abnormalities are observed. No specific symptoms may present in case of overdose; however, appropriate treatment and observation based on clinical symptoms are necessary. This medication is not recommended for use in children, as safety and efficacy have not been established. Lastly, this medication must be taken according to a physician's prescription and instructions, and any uncomfortable symptoms or adverse reactions experienced during use should be reported to medical staff immediately.
Congestive heart failure, excessive and rapid weight change, difficulty breathing, edema, fluid retention, inadequate blood sugar control, upper respiratory infection, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, urinary tract infection, low back pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, cardiovascular complications leading to death, hospitalization due to worsening congestive heart failure, emergency room visit due to congestive heart failure, progression of congestive heart failure, adverse reactions related to edema, liver failure, diabetic macular edema accompanied by vision reduction, elevated serum ALT levels, decreased hemoglobin, elevated serum creatine kinase, bladder cancer, dizziness, loss of appetite, constipation, upper abdominal pain, chest pain, fatigue, weakness, dyspepsia, nausea, difficulty breathing, itching, chest discomfort, tremors, chills, gastrointestinal disorders, abdominal pain, epigastric discomfort, numbness, muscle rigidity, discomfort in the head, worsening liver disease, urticaria, eczema, joint pain, knee abnormalities, arm weakness, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simple herpes, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, heart failure, fracture
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a light-resistant, airtight container and kept away from humid areas. The storage temperature should be generally between 15 to 30 degrees Celsius, ideally at about 25 degrees Celsius in a cool place.
White round tablet
30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
YuYu Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kyungdong Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.